TRAIL-R3 is a decoy protein which can be bypassed by targeting TRAIL-R1 and TRAIL-R2 by antibodies and thus can be used as a treatment for AML patients (112). This evidence concerns the gene TNFRSF10A and acute myeloid leukemia.